Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03174366 · ClinicalTrials.gov registry record · Phase 3
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
A Phase 3 study of Charcot Joint of Foot, sponsored by Western University of Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT03174366: Completed Phase 3 study of Charcot Joint of Foot, sponsored by Western University of Health Sciences.
NCT03174366 is a Phase 3 study of Charcot Joint of Foot that has completed, run by Western University of Health Sciences. The registered enrollment target is 7 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03174366, a Phase 3 study of Charcot Joint of Foot, has completed, sponsored by Western University of Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb. Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.
Primary Outcome
Incidence of Treatment-Emergent Adverse Events \[Safety and Tolerability\]
Conditions Studied
Interventions
- DRUG Denosumab
Study Locations (1)
California
- Western University of Health Sciences - Pomona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2019-03-06 |
| Phase | Phase 3 |
What the finished NCT03174366 record still lists
NCT03174366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Charcot Joint of Foot appearing as the primary indexed condition, and to 1 intervention - of which Denosumab is the first listed.
NCT03174366 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03174366 about?
NCT03174366 is a clinical study titled "Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy". Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to bel...
What is the current status of trial NCT03174366?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2017-05-16. Estimated completion is 2019-03-06.
What conditions does trial NCT03174366 study?
This clinical trial studies the following conditions: Charcot Joint of Foot.
What interventions are being tested in trial NCT03174366?
The interventions under investigation include: Denosumab (DRUG).
Who is sponsoring clinical trial NCT03174366?
This trial is sponsored by Western University of Health Sciences, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03174366 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03174366's enrollment target sits among peer trials
7 1995th of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI